{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:14:21Z","timestamp":1789874061732,"version":"4.0.1"},"reference-count":20,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,5,26]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>The overall response rate following 4 induction cycles of VTD prior to ASCT is higher than that of 4 cycles of VCD.<\/jats:p>","DOI":"10.1182\/blood-2016-01-693580","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T23:45:17Z","timestamp":1458603917000},"page":"2569-2574","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":248,"title":["VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial"],"prefix":"10.1182","volume":"127","author":[{"given":"Philippe","family":"Moreau","sequence":"first","affiliation":[{"name":"University Hospital, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[{"name":"University Hospital, Bordeaux, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[{"name":"University Hospital, Caen, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Caillot","sequence":"additional","affiliation":[{"name":"University Hospital, Dijon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Chaleteix","sequence":"additional","affiliation":[{"name":"University Hospital, Clermont-Ferrand, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murielle","family":"Roussel","sequence":"additional","affiliation":[{"name":"Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Garderet","sequence":"additional","affiliation":[{"name":"University Hospital Saint-Antoine, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Royer","sequence":"additional","affiliation":[{"name":"University Hospital, Amiens, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Brechignac","sequence":"additional","affiliation":[{"name":"University Hospital Avicenne, Bobigny, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mourad","family":"Tiab","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Departemental, La Roche Sur Yon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Puyade","sequence":"additional","affiliation":[{"name":"University Hospital, Poitiers, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Escoffre","sequence":"additional","affiliation":[{"name":"University Hospital, Rennes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Stoppa","sequence":"additional","affiliation":[{"name":"Institut Paoli-Calmette, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"University Hospital, Lille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Pegourie","sequence":"additional","affiliation":[{"name":"University Hospital, Grenoble, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Driss","family":"Chaoui","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Departemental, Argenteuil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jaccard","sequence":"additional","affiliation":[{"name":"University Hospital, Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borhane","family":"Slama","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Departemental, Avignon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Marit","sequence":"additional","affiliation":[{"name":"University Hospital, Bordeaux, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Laribi","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Departmental, Le Mans, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Godmer","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Departmental, Vannes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile","family":"Luycx","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Departemental, Lorient, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Eisenmann","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Departemental, Mulhouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Allangba","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Departemental, Saint-Brieuc, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoun","family":"Dib","sequence":"additional","affiliation":[{"name":"University Hospital, Angers, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Araujo","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Departemental, Bayonne, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Fontan","sequence":"additional","affiliation":[{"name":"University Hospital, Besancon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Belhadj","sequence":"additional","affiliation":[{"name":"University Hospital, Creteil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Wetterwald","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Departemental, Dunkerque, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Dorvaux","sequence":"additional","affiliation":[{"name":"University Hospital, Metz, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Fermand","sequence":"additional","affiliation":[{"name":"University Hospital Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rodon","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Departemantal, Perigueux, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Kolb","sequence":"additional","affiliation":[{"name":"University Hospital, Reims, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Glaisner","sequence":"additional","affiliation":[{"name":"Institut Curie, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Valere","family":"Malfuson","sequence":"additional","affiliation":[{"name":"Hopital des Arm\u00e9es, Clamart, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lenain","sequence":"additional","affiliation":[{"name":"Centre Henri Becquerel, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Biron","sequence":"additional","affiliation":[{"name":"University Hospital, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Planche","sequence":"additional","affiliation":[{"name":"University Hospital, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Caillon","sequence":"additional","affiliation":[{"name":"University Hospital, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Avet-Loiseau","sequence":"additional","affiliation":[{"name":"Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dejoie","sequence":"additional","affiliation":[{"name":"University Hospital, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Attal","sequence":"additional","affiliation":[{"name":"Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"23","key":"2019111904225638100_B1","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1182\/blood-2011-02-297325","article-title":"International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.","volume":"117","author":"Cavo","year":"2011","journal-title":"Blood"},{"issue":"20","key":"2019111904225638100_B2","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma.","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2019111904225638100_B3","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.6004\/jnccn.2015.0167","article-title":"Multiple myeloma. Version 2.2016.","volume":"13","author":"Anderson","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"26","key":"2019111904225638100_B4","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","article-title":"Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.","volume":"31","author":"Sonneveld","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111904225638100_B5","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1182\/blood-2014-03-544759","article-title":"How we manage autologous stem cell transplantation for patients with multiple myeloma.","volume":"124","author":"Gertz","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111904225638100_B6","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"2019111904225638100_B7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2141.2011.08949.x","article-title":"A comparison of lenalidomide\/dexamethasone versus cyclophosphamide\/lenalidomide\/dexamethasone versus cyclophosphamide\/bortezomib\/dexamethasone in newly diagnosed multiple myeloma.","volume":"156","author":"Khan","year":"2012","journal-title":"Br J Haematol"},{"issue":"19","key":"2019111904225638100_B8","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"9758","key":"2019111904225638100_B9","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"22","key":"2019111904225638100_B10","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1182\/blood-2011-05-355081","article-title":"Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111904225638100_B11","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study.","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019111904225638100_B12","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/leu.2015.80","article-title":"Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.","volume":"29","author":"Mai","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"2019111904225638100_B13","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"11","key":"2019111904225638100_B14","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood-2010-08-300863","article-title":"Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial.","volume":"117","author":"Moreau","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2019111904225638100_B15","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ajh.24107","article-title":"Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma.","volume":"90","author":"Binder","year":"2015","journal-title":"Am J Hematol"},{"issue":"12","key":"2019111904225638100_B16","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1038\/leu.2015.274","article-title":"Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.","volume":"29","author":"Cavo","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"2019111904225638100_B17","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/ajh.23835","article-title":"Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.","volume":"89","author":"Tacchetti","year":"2014","journal-title":"Am J Hematol"},{"issue":"5","key":"2019111904225638100_B18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"issue":"25","key":"2019111904225638100_B19","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","article-title":"Frontline transplant program with bortezomib, lenalidomide, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in multiple myeloma patients: a phase II study of the Intergroupe Francophone du My\u00e9lome (IFM).","volume":"32","author":"Roussel","year":"2014","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111904225638100_B20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.391.391","article-title":"Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the Intergroupe Francophone du Myelome (IFM\/DFCI 2009 trial) [abstract].","volume":"126","author":"Attal","year":"2015","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/21\/2569\/1393826\/2569.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/21\/2569\/1393826\/2569.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T04:23:05Z","timestamp":1574137385000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/127\/21\/2569\/35189\/VTD-is-superior-to-VCD-prior-to-intensive-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,26]]},"references-count":20,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2016,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-01-693580","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726230355.793522203","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.726230355.793520188","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,26]]}}}